TNFSF10 and acute myeloid leukemia: Furthermore, we found that pre-treatment AML patients with serum TRAIL values lower than the median (68.54 pg/ml) had a significantly shorter OS than patients with a higher TRAIL value, p = 0.03 (Fig. 1).